Monograph Development: Why and When to Participate (eBook)

Author(s)J. Mark Wiggins, Joseph A. Albanese

Monographs are developed based on the submission of information and materials from a company having regulatory approval for the product, and this submission feeds into the pharmacopoeia revision process.

Pharmacopoeia Compliance Series

This article explores another proactive advocacy approach that a bio/pharmaceutical company may take through participation in the development of new and revised monographs in the various pharmacopoeias.

This article is part of a series that will be published in 2019–2020. View all articles in this series.

Read this article in Pharmaceutical Technology’s March 2020 Regulatory Sourcebook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook, March 2020
March 2020
Pages: 14–23

Citation

When referring to this article, please cite it as J.M. Wiggins and J.A. Albanese, “Monograph Development: Why and When to Participate," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2020).

Articles in this issue

almost 6 years ago

Article

Resources, Guidelines, and Guidance Documents

almost 6 years ago

Article

Regulatory and Standard Setting Organizations

almost 6 years ago

Article

A ‘New Normal’ for Quality?

almost 6 years ago

Article

Pharmacopoeia Compliance: Putting It All Together; What Is on the Horizon (eBook)

almost 6 years ago

Article

A Practical Approach to Pharmacopoeia Compliance (eBook)

almost 6 years ago

Article

Inside FDA’s New Gene and Cell Therapy Guidances

almost 6 years ago

Article

ALCOA+ and Data Integrity

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!